<DOC>
	<DOCNO>NCT00581087</DOCNO>
	<brief_summary>DHEA prevents reverse chronic hypoxic pulmonary hypertension chronic hypoxic-pulmonary hypertension model rat . However , study perform human . The purpose study determine DHEA effective treatment respiratory pulmonary hypertension adult Chronic Obstructive Pulmonary Disease ( COPD ) exercise capacity haemodynamic variable . Patients receive randomization either 200 mg oral DHEA placebo one-year period . Evaluation concern clinical parameter , echocardiography right catheterization treatment . Primary end-point six-minute walk test . This prospective double blind , randomize , placebo control study realize four university hospital France : Bordeaux , Strasbourg , Toulouse Limoges . Eight patient pulmonary hypertension ( New York Heart Association functional class III IV ) associate COPD include pilot study 2004 2005 . Inclusion criterion : COPD define FEV1/FVC &lt; 70 % reference value ; rest mean pulmonary artery pressure ( assessment right pulmonary catheterization ) ≥ 25mmHg mean pulmonary capillary wedge pressure ≤ 15mmHg , PaO2 ≤ 60mmHg rest PaO2 ≥ 60mmHg associate significant fall O2 saturation exercise ; oxygen treatment initiate six month previously . Exclusion criterion : clinical respiratory instability three month inclusion study ; corticosteroid therapy ( &gt; 0.5mg/kg/day prednisolone equivalent ) ; hepatic ( prothrombin time &lt; 50 % ) renal ( creatininemia &gt; 130µmol/L ) failure ; diabetes ; leave ventricular dysfunction ; PSA ( prostatic antigen &gt; 2,5ng/ml ) past history diagnosis cancer . The study conduct accordance Good Clinical Practices Guidelines . The study protocol approve ethic review board University Hospital Bordeaux ( France ) . Written inform consent obtain patient investigation conduct accord institutional guideline Helsinki principle . This trial conduct enrollment 2004 2005 , register ClinicalTrials.gov precede policy . ( Study design : The dose oral DHEA administer 200 mg daily three month . At baseline three month treatment , clinical evaluation include 6MWT , Borg dyspnea index , systolic diastolic blood pressure , right heart catheterisation , lung function test serum DHEA level perform . )</brief_summary>
	<brief_title>Study Dehydroepiandrosterone ( DHEA ) Respiratory Pulmonary Hypertension Adults</brief_title>
	<detailed_description>• Principal Objective : Efficacy DHEA exercise capacity ( six-minute walk test ) - Secondary Objective : - Efficacy DHEA pulmonary arterial pressure ( mean , systolic diastolic ) , systemic arterial pressure , pulmonary vascular resistance - Safety DHEA treatment - Observance treatment DHEA - Study design : Double-blind , randomize , placebo-controlled Phase III study . Patients randomize two parallel group receive either 200 mg oral DHEA placebo one-year treatment . This multicentric study department respiratory medicine Bordeaux , Strasbourg , Limoges Toulouse ( France ) . • Inclusion criterion : - Age ≥ 18 year old ≤ 75 year old ( * ) - Chronic Obstructive Pulmonary Disease VEMS/CV &lt; 70 % ( ** ) - Respiratory pulmonary hypertension mean pulmonary arterial pressure ≥ 25 mmHg ( ** ) relate normal pulmonary capillary pressure assess catheterization right side heart ( pulmonary capillary wedge pressure ≤12mmHg ) - PO2 ≤ 60 mmHg assess arterial gazometry ease ( ** ) PO2 &gt; 60 mmHg , relate high hypoxemia exercise ( six-minute walk test ) - Oxygenotherapy 6 month pre-screening - Written inform consent ( * ) Inclusion young adult concern COPD relate asthma cystic fibrosis ( ** ) Criteria assess last health check last exams COPD diagnosis - Exclusion criterion : - Clinical instability and/or respiratory exacerbation within previous three month - Clinical instability and/or respiratory exacerbation dangerous catheterization - Pregnancy ( ßHCG &gt; 20 UI /l ) breastfeed go - General corticotherapy &gt; 0,5 mg/kg/j prédnisolone equivalent - Hepatic insufficiency ( TP &lt; 50 % ) renal insufficiency ( creatininemia &gt; 130 µmol/l ) diabetes mellitus type I II ( treated oral antidiabetic oral insulin ) - Left-heart failure ( coronary heart disease and/or leave valvulopathy ) - High level prostatic specific antigen ( PSA ) ( &gt; 2,5ng/ml ) - Previous cancer treatment go - Study plan : After screen evaluation write consent document , patient randomize two group placebo DHEA , one year treatment . • Number subject : 60 patient base increase 30 % primary end-point , ( six-minute walk test ) , i.e. , 30 patient include group .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Age ≥ 18 year old ≤ 75 year old ( * ) Chronic Obstructive Pulmonary Disease FEVs/VC &lt; 70 % ( ** ) Respiratory pulmonary hypertension mean pulmonary arterial pressure ≥ 25 mmHg ( ** ) relate normal pulmonary capillary pressure assess catheterization right side heart ( pulmonary capillary wedge pressure ≤12mmHg ) PO2 ≤ 60 mmHg assess arterial gazometry ease ( ** ) PO2 &gt; 60 mmHg , relate high hypoxemia exercise ( sixminute walk test ) Oxygenotherapy 6 month prescreening Written informed consent ( * ) Inclusion young adult concern COPD relate asthma cystic fibrosis ( ** ) Criteria assess last health check last exams COPD diagnosis clinical instability and/or respiratory exacerbation within previous three month clinical instability and/or respiratory exacerbation dangerous catheterization Pregnancy ( ßHCG &gt; 20 UI /l ) breastfeed go General corticotherapy &gt; 0,5 mg/kg/day prédnisolone equivalent Hepatic insufficiency ( TP &lt; 50 % ) renal insufficiency ( creatininemia &gt; 130 µmol/l ) diabetes mellitus type I II ( treated oral antidiabetic insulin ) Leftheart failure ( coronary heart disease and/or leave valvulopathy ) High level prostatic specific antigen ( PSA ) ( &gt; 2,5ng/ml ) Cancer antecedent treatment go</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hypertension , pulmonary</keyword>
	<keyword>DHEA</keyword>
	<keyword>six-minute walk test</keyword>
	<keyword>pulmonary arterial pressure</keyword>
</DOC>